journal
https://read.qxmd.com/read/33308288/partial-response-to-erlotinib-in-a-patient-with-imatinib-refractory-sacral-chordoma
#1
JOURNAL ARTICLE
Saurav Verma, Surya Prakash Vadlamani, Shamim Ahmed Shamim, Adarsh Barwad, Sameer Rastogi, S T Arun Raj
BACKGROUND: Chordoma is a rare, slow growing and locally aggressive mesenchymal neoplasm with uncommon distant metastases. It is a chemo-resistant disease with surgery and radiotherapy being the mainstay in treatment of localized disease. In advanced disease imatinib has a role. We report a case of metastatic sacral chordoma with symptomatic and radiological response to erlotinib post-progression on imatinib. CASE PRESENTATION: A 48-year-old male with a sacral chordoma underwent partial sacrectomy followed by post-operative radiotherapy...
December 12, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33308312/locally-recurrent-extraskeletal-myxoid-chondrosarcoma-of-the-shoulder-a-case-of-complete-neoadjuvant-radiotherapy-response
#2
JOURNAL ARTICLE
Luca Improta, Sergio Valeri, Rossana Alloni, Chiara Pagnoni, Francesco Mallozzi Santa Maria, Beniamino Brunetti, Carlo Greco, Irene Aprile, Mirella Maselli, Bruno Vincenzi, Alessandro Gronchi
BACKGROUND: Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue tumor that typically affects the lower limbs of men between the ages of 50 and 60. EMC of the shoulder is rare with a high risk of local recurrence and distant metastasis. A planned surgical excision in sarcoma referral centers (SRCs) is mandatory to obtain the best outcome. The role of chemotherapy (CHT) and Radiotherapy (RT) on soft tissue chondrosarcoma is still controversial. CASE PRESENTATION: A 47-year-old man presented to our referral center with a history of EMC in the right shoulder excised with microscopic positive surgical margins in a non-referral center...
December 11, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33372627/the-role-of-prognostic-nutritional-index-in-the-management-of-pulmonary-sarcomatoid-carcinoma
#3
JOURNAL ARTICLE
Yan Wang, Yu Cao, Junfeng Liu
BACKGROUND: Pulmonary sarcomatoid carcinoma is characterized by poor survival rates compared with other non-small cell lung cancer. Prognostic nutritional index has significant prognostic value in many malignant tumors. We conducted this retrospective study to investigate the role of prognostic nutritional index in patients with pulmonary sarcomatoid carcinoma and to determine prognostic factors. METHODS: Of 8176 patients with resected lung cancer in a single high-volume institution between 2008 and 2015, 91 patients with pathologically diagnosed sarcomatoid carcinoma were included in our study and evaluated...
December 7, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33292592/ifosfamide-induced-encephalopathy-the-eeg-with-frontal-intermittent-delta-activity-and-rapid-resolution-with-methylene-blue-a-case-report
#4
JOURNAL ARTICLE
Juliette E Hamilton, Michael Alexander, Fergal C Kelleher
BACKGROUND: Encephalopathy is an established side effect of the chemotherapeutic agent, ifosfamide, occurring in 10-30% of cases. The EEG commonly shows non-specific features of encephalopathy, and rarely shows frontal intermittent rhythmic delta activity (FIRDA). CASE PRESENTATION: This is a case report of a 71 year old woman with pleomorphic sarcoma, who developed ifosfamide-induced encephalopathy with her second dose of ifosfamide. It shows the characteristic EEG findings that have been described previously with ifosfamide-induced encephalopathy and additionally the unusual and rare finding of FIRDA...
November 28, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33292569/simultaneous-diagnosis-of-liver-pecoma-in-a-family-with-known-li-fraumeni-syndrome-a-case-report
#5
JOURNAL ARTICLE
María Del Mar Galera López, Iván Márquez Rodas, Carolina Agra Pujol, Ángela García Pérez, Enrique Velasco Sánchez, Rosa Álvarez Álvarez
BACKGROUND: Li-Fraumeni syndrome (LFS) is an autosomal dominant hereditary disease. It is associated with the loss of function of the p53 protein and an increased risk of malignant tumor development at early age. The most frequently detected tumors include breast cancer, sarcomas, leukemia, brain tumors, and adrenocortical carcinomas. While sarcomas account for only 1% of solid tumors, they are more frequently detected in these families. CASE PRESENTATION: We report a simultaneous diagnosis of hepatic perivascular epithelioid cell tumor (PEComa), a very rare subtype of sarcoma, in two siblings with a LFS...
November 24, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33292480/solitary-extrapleural-fibrous-tumor-with-hepatic-bilobar-metastases-multimodal-approach-treatment
#6
JOURNAL ARTICLE
Maitane I Orue-Echebarria, Laura Garciafília, Luis Rodriguez-Bachiller, Benjamín Díaz-Zorita, Enrique Velasco, Enrique Ramón, Carolina Agra, Arturo Colón Rodríguez
BACKGROUND: Solitary fibrous tumor is an unusual fibroblastic mesenchymal neoplasm typically described in the pleura. It may appear anywhere with a varied anatomic distribution and essentially it can develop from any soft tissue or visceral location. Its course is usually indolent and it rarely causes distant metastases, so it has a prolonged survival rate. It sometimes presents itself as a disseminate disease being the liver the most frequently involved location. In these occasions, the management should be discussed in a multidisciplinary tumor committee formed by surgeons, oncologists and radiologists...
November 18, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33292545/preoperative-accelerated-radiotherapy-combined-with-chemotherapy-in-a-defined-cohort-of-patients-with-high-risk-soft-tissue-sarcoma-a-scandinavian-sarcoma-group-study
#7
JOURNAL ARTICLE
Kirsten Sundby Hall, Øyvind S Bruland, Bodil Bjerkehagen, Elisabet Lidbrink, Nina Jebsen, Hans Hagberg, Karin Papworth, Oskar Hagberg, Clement Trovik, Henrik Bauer, Mikael Eriksson
BACKGROUND: We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX, group B, comprised of patients in a defined cohort with locally advanced STS considered at high risk for intralesional surgery. These patients received preoperative accelerated radiotherapy, together with neoadjuvant and adjuvant chemotherapy. Herein we report the results of this group B...
November 17, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33292535/seeking-international-consensus-on-approaches-to-primary-tumour-treatment-in-ewing-sarcoma
#8
JOURNAL ARTICLE
Craig Gerrand, Jessica Bate, Beatrice Seddon, Uta Dirksen, R Lor Randall, Michiel van de Sande, Paul O'Donnell, John Tuckett, David Peake, Lee Jeys, Asif Saifuddin, Mel Grainger, Jeremy Whelan
BACKGROUND: The local treatment of Ewing sarcoma of bone involves surgery, radiotherapy or both. The selection of treatment depends on the anatomical extent of the tumour, the effectiveness of the proposed treatment, its morbidity, and the expectation of cure. However, not only are there variations in the approach to local treatment between individual patients, but also between treatment centres and countries. Our aim was to explore variation in practice and develop consensus statements about local treatment...
November 17, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33292518/glomus-tumors-with-malignant-features-of-the-extremities-a-case-series
#9
JOURNAL ARTICLE
Taylor R Wood, Jonathan B McHugh, Geoffrey W Siegel
BACKGROUND: Malignant glomus tumors are exceedingly rare, however they can be locally aggressive and have the potential to metastasize. There is limited information available in the literature regarding treatment and outcomes, therefore we present a case series of 5 patients with glomus tumors with malignant features confined to the extremities that have presented to our tertiary sarcoma center within the last 20 years. This is the largest case series of its kind in the malignant glomus tumor literature, to our knowledge...
October 30, 2020: Clinical Sarcoma Research
https://read.qxmd.com/read/33133513/glomus-tumors-with-malignant-features-of-the-extremities-a-case-series
#10
JOURNAL ARTICLE
Taylor R Wood, Jonathan B McHugh, Geoffrey W Siegel
Background: Malignant glomus tumors are exceedingly rare, however they can be locally aggressive and have the potential to metastasize. There is limited information available in the literature regarding treatment and outcomes, therefore we present a case series of 5 patients with glomus tumors with malignant features confined to the extremities that have presented to our tertiary sarcoma center within the last 20 years. This is the largest case series of its kind in the malignant glomus tumor literature, to our knowledge...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32944215/when-does-a-new-sarcoma-exist
#11
EDITORIAL
Paolo G Casali, Angelo Paolo Dei Tos, Alessandro Gronchi
No abstract text is available yet for this article.
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32944214/survival-of-soft-tissue-sarcoma-patients-after-completing-six-cycles-of-first-line-anthracycline-containing-treatment-an-eortc-stbsg-database-study
#12
JOURNAL ARTICLE
Arie Jan Verschoor, Saskia Litière, Sandrine Marréaud, Ian Judson, Maud Toulmonde, Eva Wardelmann, Axel LeCesne, Hans Gelderblom
BACKGROUND: Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. Currently several options to improve survival after doxorubicin based chemotherapy are being studied. This study reports on survival after completing 6 cycles of doxorubicin containing first line treatment, which is important when designing studies trying to improve outcomes of first line treatment. METHODS: A retrospective database analysis was performed on 2045 patients from 12 EORTC sarcoma trials (inclusion period 1980-2012) receiving first line doxorubicin based chemotherapy for advanced soft tissue sarcoma in order to establish progression free survival and overall survival after completing 6 cycles of first line doxorubicin based chemotherapy...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32874547/anthracycline-based-and-gemcitabine-based-chemotherapy-in-the-adjuvant-setting-for-stage-i-uterine-leiomyosarcoma-a-retrospective-analysis-at-two-reference-centers
#13
JOURNAL ARTICLE
Giovanni Fucà, Chiara Fabbroni, Rosanna Mancari, Sara Manglaviti, Giorgio Bogani, Elena Fumagalli, Rossella Bertulli, Carlo Morosi, Paola Collini, Francesco Raspagliesi, Nicoletta Colombo, Paolo G Casali, Roberta Sanfilippo
Background: Radically resected early uterine leiomyosarcoma (eULMS) is still marked by a poor prognosis. Adjuvant strategies investigated up to now have not been corroborated by controlled studies. We retrospectively reviewed the clinical outcome of eULMS patients treated with adjuvant anthracycline-based or gemcitabine-based chemotherapy at two Italian reference centers. Methods: In this explorative, retrospective, cohort analysis, we included all the consecutive patients with radically resected eULMS treated at two centers between 1997 and 2017...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32864096/long-lasting-response-with-trabectedin-monotherapy-in-relapsed-metastatic-mesenchymal-chondrosarcoma
#14
Ghazal Tansir, Sameer Rastogi, Adarsh Barwad, Ekta Dhamija
Background: Mesenchymal chondrosarcoma is an exceedingly rare malignancy, accounting for around 5% of all patients with chondrosarcoma. It is a translocation-related sarcoma that tends to have both local and distant recurrences. Surgery is the mainstay of treatment in localised cases however treatment of advanced cases remains a challenge. The rarity of the disease precludes dedicated clinical trials and hence guidelines for its management are not well defined. The dearth in literature makes it pertinent that the cases treated with newer therapies must be reported to contribute to existing knowledge...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32864095/paraneoplastic-dermatomyositis-associated-with-metastatic-leiomyosarcoma-of-unknown-primary
#15
Eve Merry, Alannah Smrke, Kapil Halai, Gulam Patel, Khin Thway, Robin L Jones, Charlotte Benson
BACKGROUND: Sarcomas are rare and heterogeneous tumours of mesenchymal origin, with over 100 histological subtypes. Paraneoplastic dermatomyositis has rarely been described in sarcoma. This is the first documented case of paraneoplastic dermatomyositis in a patient with metastatic leiomyosarcoma. CASE PRESENTATION: A 43-year-old female diagnosed with metastatic leiomyosarcoma of unknown primary presented with a mild rash in sun-exposed areas of her face and upper chest, with no other neuromuscular symptoms...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32782782/successful-treatment-of-lipofibromatosis-like-neural-tumor-of-the-lumbar-spine-with-an-ntrk-fusion-inhibitor
#16
Megan Dupuis, Yulei Shen, Christian Curcio, Jeanne M Meis, Wei-Lien Wang, Behrang Amini, Laurence Rhines, Jacquelyn Reuther, Angshumoy Roy, Kevin E Fisher, Anthony P Conley, J Andrew Livingston
Background: Lipofibromatosis-like neural tumors (LPF-NT) are a newly identified class of rare mesenchymal neoplasms. Current standard of care therapy is surgical resection alone; there are no chemotherapies or molecular targeted therapies that have been shown to be effective in patients who are not surgical candidates due to either tumor bulk or location. Most LPF-NT harbor NTRK fusions, although the therapeutic significance of these fusions has not been previously demonstrated in this malignancy...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32782781/treatment-of-gastrointestinal-tumor-gist-of-the-rectum-requiring-abdominoperineal-resection-following-neoadjuvant-imatinib-a-cost-effectiveness-analysis
#17
JOURNAL ARTICLE
Mohamad Farid, Johnny Ong, Claramae Chia, Grace Tan, Melissa Teo, Richard Quek, Jonathan Teh, David Matchar
Background: Neoadjuvant imatinib for gastrointestinal stromal tumors (GIST) of the rectum can reduce, but may not eliminate, risk of surgical morbidity from permanent bowel diversion. We sought to evaluate the cost-effectiveness of alternative strategies in rectal GIST patients requiring abdominoperineal resection following neoadjuvant imatinib. Methods: We developed a Markov model using a healthcare payers' perspective to estimate costs in 2017 Singapore dollars (SGD) and quality adjusted life years (QALYs) for upfront abdominoperineal resection (UAPR) versus continued imatinib until progression (CIUP) following 1 year of neoadjuvant imatinib...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32765826/a-case-report-of-kaposiform-haemangioendothelioma-response-with-propranolol-and-steroids
#18
Saurav Verma, Ekta Dhamija, Adarsh Barwad, Venkatesan S Kumar, Sameer Rastogi
BACKGROUND: Kaposiform haemangioendothelioma is a rare vascular tumor and may involve skin, deep soft tissue or bone. It is a locally aggressive tumor usually seen in infants. Here we report a case of kaposiform hemagioendothelioma in a child who responded to propranolol and steroids. CASE PRESENTATION: A 3-year-old male child presented with a swelling below his right knee with characteristic violet skin lesion. There was no evidence of Kasabach-Merritt phenomenon...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32670544/chemotherapy-improves-distant-control-in-localized-high-grade-soft-tissue-sarcoma-of-the-extremity-trunk
#19
JOURNAL ARTICLE
Victoria T Rizk, Arash O Naghavi, Andrew S Brohl, David M Joyce, Odion Binitie, Youngchul Kim, John P Hanna, Jennifer Swank, Ricardo J Gonzalez, Damon R Reed, Mihaela Druta
BACKGROUND: Soft tissue sarcomas (STS) are rare and heterogeneous tumors making chemotherapy use controversial. Our goal was to identify a subset of patients with primary STS that benefit with the addition of chemotherapy. METHODS: A retrospective chart review included intermediate to high-grade localized primary STS of the extremity/trunk, and tumor size > 5 cm. The effect of chemotherapy was evaluated for local control (LC), distant control (DC), progression free survival (PFS), and overall survival (OS)...
2020: Clinical Sarcoma Research
https://read.qxmd.com/read/32670543/good-and-sustained-response-to-pembrolizumab-and-pazopanib-in-advanced-undifferentiated-pleomorphic-sarcoma-a-case-report
#20
Shalabh Arora, Sameer Rastogi, Shamim Ahmed Shamim, Adarsh Barwad, Maansi Sethi
Background: Conventional cytotoxic agents and pazopanib are approved for advanced soft tissue sarcomas but have low response rates and modest survival benefits. Recently, immune checkpoint inhibitors have shown clinically meaningful activity. The combination of pazopanib and immunotherapy has shown synergism in various other malignancies but has not been fully explored in advanced soft tissue sarcomas. Case presentation: A 63 year old woman with metastatic undifferentiated pleomorphic sarcoma progressed after two lines of palliative combination chemotherapy-doxorubicin with olaratumab, and gemcitabine with docetaxel...
2020: Clinical Sarcoma Research
journal
journal
43933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.